NutraVesta ProVen Reviews : Meet the New Weight Loss Supplement That Actually Boosts Your Health

NutraVesta ProVen Reviews : Meet the New Weight Loss Supplement That Actually Boosts Your Health

  • August 5, 2020

There’s definitely no shortage of options on the weight supplement market, but how good are they really for you in the long run? After all, it’s not worth caving into the hype if the pills don’t do anything, or worse, if they trigger a chain of dangerous side effects along with those lost pounds. This is the consumer dilemma that NutraVesta ProVen wanted to address. This new, all-natural formula boasts potent ingredients that have been scientifically tested in advance, and that should help you lose weight without harming your overall health. More than that, NutraVesta ProVen packs a carefully selected blend of antioxidants that target three key areas and improve your health and wellness.

(Best Value) Click Here for the Latest Discounts on NutraVesta ProVen

If that sounds uncommon – well, it really is. Health and weight loss are connected, but that’s rarely reflected in the practices of supplement manufacturers. NutraVesta ProVen wanted to change that and bring back attention to the fact that excess weight gain is first and foremost a health concern. This is why this range of supplements was designed with safety in mind and, apart from weight loss support, it also delivers many health benefits. Numerous studies have shown that when we exceed the ideal BMI, excess weight becomes more than an aesthetic or self-confidence concern. Extra pounds put extra strain on the cardiovascular system, and that leads to a series of health complications. Therefore, the right weight loss supplement should have an all-rounded approach: it should facilitate weight loss, while at the same time boosting detoxification and heart health.

Does NutraVesta ProVen really work? Read NutraVesta ProVen Reviews before you buy! 

NutraVesta ProVen Ingredients

The formula behind NutraVesta ProVen is based on all-natural ingredients that activate the body’s metabolism and activate key health functions. For example, turmeric, which is rich in curcumin, acts as a potent antioxidant that activates the body’s hormonal responses. Green tea leaves, which are one of the tried and tested champions of weight loss, also have strong antioxidant properties. Garlic bulb boosts immunity, amplifying the effects of Selenium, which was also included in the formula. NutraVesta ProVen consists of a carefully selected mix of 3 Asian Mushrooms (Reishi, maitake, and shitake), which encourage the activity of white blood cells – key agents in keeping infections at bay. Other ingredients in the formula include: Panax ginseng, Bioflavonoids, Vitamins C and E, Indian rhubarb, and beta-glucan. 

One of the harmful side effects of being overweight is that the body’s ability to fight off infection starts to decrease. So, in addition to facilitating weight loss, NutraVesta ProVen ingredients strengthen the immune system, so it can once again fight off illnesses.

See here the full list of ingredients.

How Does NutraVesta ProVen Benefit Your Health?

Seeing your weight loss pills work is great, but are they harming your health in the long run? In the case of NutraVesta ProVen, no, they don’t. On the contrary, this supplement has a whole array of health benefits and focuses on three major areas:

  • Keeping your heart healthy. The heart is the first organ to suffer from excess fat, which is why NutraVesta is packed with antioxidants that protect it and may reduce the risk of cardiovascular diseases down the line.
  • Reduces fatigue. Oftentimes when trying to lose weight, you may feel tired and unmotivated. The ingredients in NutraVesta boost energy levels so that you can focus and feel great from morning to evening.
  • Helps you lose weight. NutraVesta helps you shed those extra pounds so that you can reach your healthiest weight in a natural, risk-free way. According to NutraVesta ProVen studies, this supplement leads to an average weight loss of 35 pounds over 3 months.

Is NutraVesta ProVen Safe?

Ideally, you want to get a slimmer figure and radiate health at the same time, so the big question is:

Is NutraVesta ProVen a safe weight loss supplement? 

Yes! NutraVesta is safe, and here’s why:

  • FDA-approved
  • Adheres to GMP (good manufacturing practices) in the US
  • Sugar-free
  • GMO-free
  • Antibiotic-free
  • Gluten-free
  • High-quality, science-backed natural formula, free from harmful artificial ingredients
  • Rigorously tested

In other words, this formula helps you lose weight and feel more confident without risking your health in the process.

NutraVesta Formula & Dosage

NutraVesta ProVen is available in capsule form for easy consumption. You don’t need to mix it with your food or integrate it with smoothies or protein shakes – you can simply take the capsules with a glass of water.

As for the dosage, NutraVesta recommends no more than 2 capsules/day. Each bottle contains 60 capsules, so one bottle should last you about a month.

Currently, one bottle of NutraVesta ProVen retails at $67, but bundle deals are also available if you want to stock up on the supplement for several months.

(Official Deal) Click Here to Claim the Best Value Deal for NutraVesta ProVen!

Are NutraVesta ProVen Reviews Positive?

All these scientific benefits sound great on paper, but what do the people have to say about them? According to the many positive NutraVesta ProVen Reviews, this weight loss supplement really works, and it has helped many people achieve their dream weight.

Those who have tried NutraVesta ProVen reported no side effects from long-term use (a rare feat for weight loss supplements) and pointed out that, compared to other pills, it helped them finally get rid of stubborn belly fat. What’s more, fans of this product point out that they felt much more energized afterwards, and that motivated them to go to the gym more often.

Another interesting thing we noticed about NutraVesta ProVen reviews is that they come from all age categories. People in their 20s, 30s, 50s, even seniors tried ProVen and were happy with the results, which goes to show how safe and effective it is. 

NutraVesta ProVen Reviews: Conclusion

As you can see, NutraVesta ProVen is a safe and effective weight loss formula that not only helps you shed extra pounds but also restores your energy and boosts your health from within. With so many positive reviews, it’s a fantastic pick for anyone who wishes to lose weight naturally.

Click here to get your NutraVesta ProVen supply at a discounted price.

First COVID-19 vaccine tested in US boosts volunteers’ immune systems, researchers say – Boston News, Weather, Sports

First COVID-19 vaccine tested in US boosts volunteers’ immune systems, researchers say – Boston News, Weather, Sports

  • July 31, 2020

The first COVID-19 vaccine tested in the U.S. revved up people’s immune systems just the way scientists had hoped, researchers reported Tuesday — as the shots are poised to begin key final testing.

“No matter how you slice this, this is good news,” Dr. Anthony Fauci, the U.S. government’s top infectious disease expert, told The Associated Press.

The experimental vaccine, developed by Fauci’s colleagues at the National Institutes of Health and Moderna Inc., will start its most important step around July 27: A 30,000-person study to prove if the shots really are strong enough to protect against the coronavirus.

But Tuesday, researchers reported anxiously awaited findings from the first 45 volunteers who rolled up their sleeves back in March. Sure enough, the vaccine provided a hoped-for immune boost.

Those early volunteers developed what are called neutralizing antibodies in their bloodstream — molecules key to blocking infection — at levels comparable to those found in people who survived COVID-19, the research team reported in the New England Journal of Medicine.

“This is an essential building block that is needed to move forward with the trials that could actually determine whether the vaccine does protect against infection,” said Dr. Lisa Jackson of the Kaiser Permanente Washington Research Institute in Seattle, who led the study.

There’s no guarantee but the government hopes to have results around the end of the year — record-setting speed for developing a vaccine.

The vaccine requires two doses, a month apart.

There were no serious side effects. But more than half the study participants reported flu-like reactions to the shots that aren’t uncommon with other vaccines — fatigue, headache, chills, fever and pain at the injection site. For three participants given the highest dose, those reactions were more severe; that dose isn’t being pursued.

Some of those reactions are similar to coronavirus symptoms but they’re temporary, lasting about a day and occur right after vaccination, researchers noted.

“Small price to pay for protection against COVID,” said Dr. William Schaffner of Vanderbilt University Medical Center, a vaccine expert who wasn’t involved with the study.

He called the early results “a good first step,” and is optimistic that final testing could deliver answers about whether it’s really safe and effective by the beginning of next year.

“It would be wonderful. But that assumes everything’s working right on schedule,” Schaffner cautioned.

Moderna’s share price jumped nearly 15 percent in trading after U.S. markets closed. Shares of the company, based in Cambridge, Massachusetts, have nearly quadrupled this year.

Tuesday’s results only included younger adults. The first-step testing later was expanded to include dozens of older adults, the age group most at risk from COVID-19. Those results aren’t public yet but regulators are evaluating them. Fauci said final testing will include older adults, as well as people with chronic health conditions that make them more vulnerable to the virus — and Black and Latino populations likewise affected.

Nearly two dozen possible COVID-19 vaccines are in various stages of testing around the world. Candidates from China and Britain’s Oxford University also are entering final testing stages.

The 30,000-person study will mark the world’s largest study of a potential COVID-19 vaccine so far. And the NIH-developed shot isn’t the only one set for such massive U.S. testing, crucial to spot rare side effects. The government plans similar large studies of the Oxford candidate and another by Johnson & Johnson; separately, Pfizer Inc. is planning its own huge study.

Already, people can start signing up to volunteer for the different studies.

People think “this is a race for one winner. Me, I’m cheering every one of them on,” said Fauci, who directs NIH’s National Institute of Allergy and Infectious Diseases.

“We need multiple vaccines. We need vaccines for the world, not only for our own country.”

Around the world, governments are investing in stockpiles of hundreds of millions of doses of the different candidates, in hopes of speedily starting inoculations if any are proven to work.

(Copyright (c) 2020 The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed.)

How to live longer: Seaweed contains fucoidan to reduce cancer risk and boosts longevity

How to live longer: Seaweed contains fucoidan to reduce cancer risk and boosts longevity

  • July 31, 2020

“Fucoidan is a natural sulphated polysaccharide that exists mainly in the cell wall matrix of various species of brown seaweed.

“The brown seaweeds containing fucoidan are widely consumed as part of the normal diet in East Asia, particularly Japan, China and Korea.

“Fucoidan mediates its activity through various mechanisms such as induction of cell cycle arrest, apoptosis and immune system activation.

“Additional activities of fucoidan have been reported that may be linked to the observed anti-cancer properties and these include induction of inflammation through the immune system, oxidative stress and stem cell mobilization.” 

Coronavirus Live Updates: New Research Boosts Evidence of Masks’ Utility, Some Experts Say

Coronavirus Live Updates: New Research Boosts Evidence of Masks’ Utility, Some Experts Say

  • July 28, 2020

The study, a Phase 3 clinical trial, will enroll 30,000 healthy people at about 89 sites around the country. Half will receive two shots of the vaccine, 28 days apart, and half will receive two shots of a saltwater placebo. Neither the volunteers nor the medical staff giving the injections will know who is getting the real vaccine.

Dr. Fauci estimated that the trial’s full enrollment of 30,000 will be completed by the end of the summer, and that results might be available by November. Even earlier results might be possible, he said, but added that he doubted that would be the case.

A second company, Pfizer, announced Monday afternoon that it would also begin a late-stage study of a coronavirus vaccine, on Tuesday. Pfizer has been working with a German company, BioNTech. Their study will also include 30,000 people, from 39 states in the United States, and from Brazil, Argentina and Germany.

The government announced last week that it had reached a $1.95 billion deal to buy 100 million doses of Pfizer’s vaccine by the year’s end, but only if the trial proves it safe and effective.

At the news briefing, Dr. Francis Collins, the director of the National Institutes of Health, said that at least three other Phase 3 trials would be starting soon, each needing 30,000 patients. Those trials will involve vaccines made by Novavax, by a collaboration of the University of Oxford and AstraZeneca, and by Johnson & Johnson. All are part of the U.S. government’s Operation Warp Speed.

Once volunteers are vaccinated, researchers will be looking for side effects and waiting to see if the vaccine significantly lowers cases of Covid-19. The study will also try to find out if it can prevent severe Covid-19 cases and death; if it can prevent infection entirely, based on lab tests; and if just one shot can prevent the illness.

Earlier tests of the vaccine showed that it stimulated a strong immune response, with minor and transient side effects like sore arms, fatigue, achiness and fever. But exactly what type of immune response is needed to prevent the illness is not known, so Phase 3 studies are essential to determine whether a vaccine really works.

Nutrition boosts your immunity | Deccan Herald

Nutrition boosts your immunity | Deccan Herald

  • July 27, 2020

Immunity is the buzzword of 2020, thanks to the prevailing pandemic. Here are some basics that can help you build your immunity.

Immunity is the ability of an organism to resist an infection or toxin with specific antibodies or sensitised blood cells. This means your body contains adequate defences to fight infection, allergy or any form of invasion.

The first line of defence comes from the skin, mucus membrane, acid in the stomach, sweat, tears and immune cells that attack all foreign cells that enter the body. This is called innate immunity. Acquired or adaptive immunity, on the other hand, is learnt by the body. When a foreign substance enters your body, the immune cells that are specific to that harmful substance attack and destroy it. 

There are natural and lifestyle causes for a reduction in immunity. Age is a natural cause. As you grow older, your immune system becomes less able.

A diet that is high in refined foods, ultra-processed foods, sugar, trans fat, and low in whole grains, fruits, vegetables, can result in chronic inflammation of the gut and suppress immunity.

Many nutrients play a role in building and maintaining immune health. 

Vitamin A is found in yellow/orange coloured fruits and vegetables, leafy greens, organ meat. Examples – mango, papaya, carrot, pumpkin, amaranth leaves, drumstick leaves, liver, egg yolk.

Vitamin C is found in Indian gooseberry (amla), guava, citrus fruits, leafy greens, coloured peppers. Examples – orange, lemon, sweet lime, drumstick leaves, parsley, green capsicum.

Vitamin D is in sunlight, fish, egg yolk, fortified milk. Vitamin E – nuts such as almonds.

Vitamin B6 is in meats, seeds, whole grains. Examples – fish, egg yolk, chicken, brown rice, maize, wheat germ, sesame seeds, sunflower seeds. Vitamin B12 is in animal foods. Examples – fish, meat, egg, milk.

Folate comes from leafy greens, whole grains. Examples – colocasia leaves, spinach, parsley, maize, pearl millet (bajra), foxtail millet, channa, horse gram, field beans. Zinc comes from seeds, dals, meats. Examples – amaranth seeds, sesame seeds, channa dal, urad dal, poultry, mutton. Iron is in dry fruits, pulses, dark green leafy vegetables. Examples – dry dates, black currants, horse gram, soybean, fenugreek leaves, coriander leaves, curry leaves, mint leaves. Selenium is in millets, pulses, leafy greens, papaya, egg, chicken. Examples – pearl millet (bajra), little millet, rajma, beet greens, mustard leaves, radish leaves, curry leaves, mint leaves.

Protein comes from pulses, dals, dairy, nuts, seeds, egg, meats. Examples – channa, rajma, tur dal, moong dal, milk, curd, almonds, chia seeds, chicken, fish.

Bioactive molecules present in spices are involved in immunity and regulation of inflammation. Some of the common spices that play a role in maintaining immunity are turmeric, onion, garlic, ginger, cardamom, cinnamon, chillies and capsicum.

Nutrition experts and organisations have always advocated well-balanced meals. A balanced meal provides all the necessary nutrients (carbohydrates, proteins, vitamins, minerals, fat, fibre), which are derived from natural food sources like cereals, millets, pulses, dals, vegetables, fruits, nuts, seeds, dairy, fats and oils, eaten in the right proportion.

Exercise influences the functioning of the immune system. It is believed that prolonged periods of intense exercise can depress immunity and lead to inflammation, but regular moderate-intensity exercise is beneficial as it reduces inflammation.

In a nutshell, follow a healthy lifestyle to maintain immune health – eat a well-balanced diet, sleep 7-8 hours daily, exercise for 45-60 minutes daily, include small bursts of physical activity throughout the day, cut stress and get direct sunlight on your skin daily.

(The writer is a nutrition and wellness consultant)

Vaccine additive boosts immune flexibility

Vaccine additive boosts immune flexibility

  • July 23, 2020

An additive known as an adjuvant can enhance responses to a vaccine containing the exotic avian flu virus H5N1, researchers report.

That can in turn strengthen both rookie and veteran elements of the immune response. The findings have implications for the effort to develop vaccines against multiple strains of flu, as well as the current push for vaccines against SARS-CoV-2.

The new study was a test of what happens when the body sees something new—in contrast to seasonal flu vaccination, which often re-activates the same memory B cells the immune system relied upon in past years.

The study provides guidance on how adjuvants might become part of a proposed “universal” flu vaccine, aimed at protecting people against a wider variety of influenza strains. In addition, vaccine designers are considering how to optimize immune responses against SARS-Cov-2, which few had encountered before 2020.

The results appear in the Proceedings of the National Academy of Sciences.

“We saw that an adjuvant makes it possible to efficiently engage both memory and naive B cells, expanding the repertoire of the antibody immune response to influenza,” says first author Ali Ellebedy, who did the study while a postdoctoral fellow in Rafi Ahmed’s lab at Emory Vaccine Center.

“For a new pathogen like SARS-CoV-2, nobody has immunity,” Ahmed says. “So the important thing is to have the vaccine bring out good responses from naïve B cells, whose frequency is low.”

“For universal flu, the situation is more complicated. You want to bring out both the cross-reactive memory cells and the naïve strain-specific cells, says Ahmed. “Looking ahead, adjuvants are going to be an important element of universal flu vaccine research.”

The particular adjuvant studied in the paper is called AS03. Its manufacturer GlaxoSmithKline is making it available for COVID-19 vaccine trials.

The AS03 adjuvant could be relevant for extending the efficacy of limited doses of protein or viral subunit-based vaccines, but less so for newer mRNA-based vaccines, Ahmed says.

The Emory Vaccine Center’s Hope Clinic performed the study, which included 50 healthy young adults, who were (most likely) exposed to other flu viruses and vaccines earlier in their lives.

The FDA approved the H5N1 vaccine, with AS03, in 2013 and the vaccine is part of the national stockpile in case of pandemic flu. More information about the AS03-adjuvanted flu vaccine is available from the FDA.

Researchers had previously observed that when the immune system encounters an unfamiliar flu virus, which occurred for many during the 2009 H1N1 pandemic, the antibodies produced are able to neutralize a broader range of viruses. This came from the skew of the antibodies toward the “stem” (or stalk) region of the viral hemagglutinin protein, versus the “head.” The stem region doesn’t mutate and change as much as the head from year to year.

A similar phenomenon occurred in the H5N1 study, because the head region of the virus was unfamiliar, but the stem region was not. Without an adjuvant, the immune response to a low dose of the H5N1 flu vaccine was poor, the researchers found.

But with the adjuvant, immune responses changed markedly between the first and second dose. A week after the first adjuvanted vaccine dose, the immune system produced broadly cross-reactive antibodies that were mostly directed against the stem.

This first wave came mostly from pre-existing memory B cells. After the second dose, the antibodies were more directed against the head, coming from strain-specific naïve B cells.

The researchers also offered an explanation for the shift in the antibody response after the second dose: essentially, the immune system is getting in its own way. After the second vaccination, the antibodies against the stem region are still in the body and they appear to be covering up those parts of the viral hemagglutinin protein, a phenomenon called “epitope blocking.”

“This is something that many flu vaccine studies have observed, but now we have a possible mechanistic explanation and good evidence for it,” Ahmed says.

Ellebedy is now an assistant professor of pathology and immunology at Washington University School of Medicine in St. Louis. Collaborators from Stanford University and the Icahn School of Medicine at Mount Sinai contributed to the paper.

The National Institute of Allergy and Infectious and the Centers of Excellence in Influenza Research and Surveillance, via Health and Human Services supported the work.

Source: Emory University

HIV research boosts race for coronavirus vaccine

HIV research boosts race for coronavirus vaccine

  • July 15, 2020

In 1984, scientists discovered the virus at the root of an alarming epidemic that was sickening otherwise healthy young men with aggressive cancers and rare, life-threatening pneumonias.

The discovery of HIV was a long-awaited moment, and Health and Human Services Secretary Margaret Heckler vowed that the scourge of AIDS would soon end. A vaccine would be ready for testing within two years, she proclaimed.

“Yet another terrible disease is about to yield to patience, persistence and outright genius,” Heckler said.

Thirty-six years later, there still is no HIV vaccine. But instead of being a cautionary tale of scientific hubris, that unsuccessful effort is leading to even greater confidence in the search for a coronavirus vaccine, from some of the same researchers who have spent their careers seeking a cure for AIDS.

Those decades of research on HIV have taught scientists an enormous amount about the immune system, honed vaccine technologies now being repurposed against the coronavirus and created a worldwide infrastructure of clinical trial networks that can be pivoted from HIV to the pathogen that causes the disease covid-19.

Laboratories, testing sites and recruitment networks that were rushed into action against the coronavirus exist because of the enormous amount of money spent on HIV. Equipment and expertise are in place. Infection control has been upgraded. Regulators are engaged.

“The investment in HIV research has made the response to covid-19 possible,” said Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston, whose work on an HIV vaccine has led to one of the leading candidates for a coronavirus vaccine.

“Bring it on, we’re ready and waiting for the covid vaccine trials,” said Linda-Gail Bekker, deputy director of the Desmond Tutu HIV Center at the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town in South Africa.

HIV is a devilishly complicated virus, deft at outwitting vaccine efforts, but there are real reasons to hope that the coronavirus will be a less resilient foe. Only by piggybacking on the HIV vaccine effort can coronavirus research move so fast.

“It’s really been a dramatic and rapid pivot for the people who are leaders in the HIV vaccine and prevention community,” said Nina Russell, deputy director for tuberculosis and HIV programs at the Bill & Melinda Gates Foundation.

Between 2000 and 2018, about $14.5 billion was spent on research toward an HIV vaccine, according to the Resource Tracking for HIV Prevention Research and Development Working Group, a project of the advocacy organization AVAC. Forty-six vaccines have survived to the preclinical or clinical stages of evaluation, and 100 were abandoned earlier in the process, the group’s data shows.

In contrast, there already are 160 vaccines under development for the novel coronavirus, a pathogen unknown to science a little more than six months ago, according to a list kept by the World Health Organization. Twenty-one of them are being evaluated in clinical settings. Billions of dollars have been committed by governments and private companies.

Now the two efforts are dovetailing.

“HIV has a lot of researchers in immunology and virology who set up labs, who have [vaccine] platforms, and they are looking to quickly repurpose to see if they can find a coronavirus vaccine,” said Meg Doherty, director of the WHO’s department of global HIV, hepatitis and STI programs.

– – –

Science is gambling that one or more of those efforts will yield and deploy a coronavirus vaccine within 12 to 18 months. Researchers are heartened by the key differences between the viruses. HIV integrates itself into the body’s cells, which means a vaccine has to start working immediately to rout the disease. People’s immune systems are not able to naturally defeat HIV, making a vaccine even more difficult to create. And it mutates much more quickly than the novel coronavirus, officially named SARS-CoV-2.

“It certainly won’t be easy, but what gives me hope is the natural history of this infection,” said Francis Collins, director of the National Institutes of Health. The large number of people who experience mild symptoms or none at all is a good sign that the immune system can defeat the virus.

“That’s different than HIV,” Collins said. “This is the kind of candidate where the vaccine should work. You know the immune system, given the appropriate priming, is able to eliminate the virus.”

Years of research on vaccines has helped scientists perfect technologies and methods that can be repurposed to the coronavirus, from RNA and DNA vaccines to those that use harmless viruses to deliver genes from the virus to cells.

Barouch, for example, has spent 15 years focused on HIV vaccine research. He developed a vaccine technology based on a harmless cold virus that could ferry specific genes into cells. Those genes code for a distinctive part of the AIDS virus to create an immune response.

The HIV vaccine based on that work, under development with the pharmaceutical giant Johnson & Johnson, was still being tested in clinical trials on a Friday in early January when Barouch was holding his annual lab retreat at Boston’s Museum of Science. A main topic of discussion was a new pneumonia in Wuhan, China, with 41 known cases and one death at the time.

The numbers seem small today, with more than 13 million cases confirmed around the globe, but Barouch and his laboratory found the news alarming even then. They decided they should do something.

That evening, the genome sequence of the virus was shared online by researchers in China, and Barouch’s lab began studying it. It didn’t take long to connect with a pharmaceutical partner, Johnson & Johnson, to work on a vaccine expected to begin human testing this month.

They repurposed the vaccine platform originally developed for HIV and Ebola by inserting genetic material that codes for the coronavirus’s distinctive spike protein. That should, in theory, trigger the immune system to develop coronavirus-fighting antibodies that protect people from infection. If it weren’t for HIV, Barouch said, his laboratory and its industry partner would not have been able to move so rapidly.

– – –

For years, the United States has built a large network to conduct the logistically complex clinical trials necessary to test HIV vaccines and preventive drugs. Larry Corey, a virologist and past president of the Fred Hutchinson Cancer Research Center in Seattle who is co-leading the Covid-19 Prevention Trials Network, said almost every aspect of running 30,000-person clinical trials for vaccines is built on the foundation of HIV.

That ranges from the data collection and biostatistics expertise needed to analyze large trials to the community relationships and experience in recruiting vulnerable people into complicated medical experiments.

The NIH unveiled its COVID-19 Prevention Trials Network on Wednesday. It is an amalgamation of several large clinical trial networks, two of them directly taken from HIV.

Leaders acknowledge that the challenges and scale are different this time: Not everyone is at risk of HIV, while the world population is vulnerable to the coronavirus.

Corey said that while a network might have spent years preparing to launch the trials now contemplated, it has to be done in only weeks.

The more mundane but essential aspects of clinical trials that ensure the results are unassailable are all in place: freezers that have been audited to show they never fail, personnel experienced at recruiting participants, operations managers accustomed to running years-long experiments.

“The NIH has invested a tremendous amount of money over the years in developing an international network capable of doing these types of trials, which requires a tremendous amount of infrastructure,” said Richard Novak, chief of infectious diseases at the University of Illinois at Chicago’s College of Medicine. “Fortunately they’re there and ready to go when something like this comes along. Otherwise, it would take years to develop.”

A critical lesson from HIV, the University of Cape Town’s Bekker said, is taking numerous approaches to a vaccine at the same time. HIV vaccine experiments often tended to be staged one after another, with the entire community waiting for the results of the best candidates. In contrast, numerous coronavirus trials are occurring simultaneously.

“If you want to do this quickly and you want to be sure you have a winner, then put a number of horses in the race that do a number of different things,” she said. And with the global population threatened, several safe, effective vaccines may be needed.

The world “may need more than one winner,” she said.

Leaders of the effort say years of experience engaging and building trust with minority, vulnerable and marginalized communities for HIV trials will help. But the coronavirus adds new complexities because of the speed and the scale of the trials. Older people in minority communities, for example, haven’t traditionally been the focus of HIV prevention trials, but they are a critical population to protect from the coronavirus.

“We’re going to need to be humble about the fact that we haven’t worked with some of these populations before,” said Nelson Michael, director of the Center for Infectious Diseases Research at the Walter Reed Army Institute of Research.

First coronavirus vaccine trialled in US boosts immune system just as scientists hoped as it’s set for final tests – The Sun

First coronavirus vaccine trialled in US boosts immune system just as scientists hoped as it’s set for final tests – The Sun

  • July 14, 2020

A VACCINE for Covid-19 has been found to induce immune responses in all of the volunteers who received it during a Phase 1 study.

The vaccine is the first to have its results published in a peer-reviewed medical journal and is expected to begin a large Phase 3 trial later this month, which is the final stage before regulators consider whether to make it available.

 a subject receives a shot in the first-stage safety study clinical trial of a potential vaccine by Moderna for COVID-19


a subject receives a shot in the first-stage safety study clinical trial of a potential vaccine by Moderna for COVID-19Credit: AP:Associated Press

Developed by Moderna, the vaccine trigged the immune response with mild side effects, including fatigue, chills, headache and muscle pain, according to a press release from the biotechnology company.

“The Company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021,” the company said.

“No matter how you slice this, this is good news,” Dr. Anthony Fauci, the U.S. government’s top infectious disease expert, told The Associated Press.

The vaccine was developed by Fauci’s colleagues at the National Institutes of Health alongside Moderna Inc.

 The vaccine was found to induce immune responses


The vaccine was found to induce immune responsesCredit: AP:Associated Press

It will start its Phase 3 study around July 27, which is a 30,000-person study to prove if the shots are strong enough to protect against the coronavirus.

In the Phase 1 study, “the goal was to look at safety and then to look at immune responses,” Dr. Lisa Jackson, a senior investigator at Kaiser Permanente Washington Health Research Institute in Seattle who was involved in the study, told CNN.

“We thought the immune responses look promising, but we don’t know whether the levels we’re seeing would actually protect against infection.

It’s really hard to know that until you do the actual efficacy trial,” she said. “So we’re laying the groundwork for the trial that will provide those answers.”

Coronavirus: Stem cell therapy boosts survival rates FIVE-fold

Coronavirus: Stem cell therapy boosts survival rates FIVE-fold

  • July 10, 2020

A stem cell therapy boosted Covid-19 survival rates five-fold for patients hooked up to ventilators, Spanish scientists have claimed.

Two out of the 13 patients in the small study died, with the remainder returning from the brink of death after doctors assumed at least 11 of them would succumb to the disease. 

Overall 70 per cent of patients saw improvements despite being in the most critical category of illness.

The researchers admitted they did not expect such positive results but cautioned their research was only on a small number of patients. 

The treatment works by injecting patients with cells taken from the fat tissue of liposuction patients – typically women under 50 years old and with no other health conditions.

These cells are thought to bolster the immune system, providing vital support for Covid-19 patients who are fighting the virus, most of whom are elderly and frail.

The stem cells also managed to tone down inflammation, which is internal swelling that has been found to be extreme and damaging in some Covid-19 patients, and can lead to organ failure.

However, chances of the treatment making it into hospitals during the pandemic are slim because scientists have faced barriers to getting stem cell treatments approved for other diseases in the past.  

The treatment, called ‘AT-MSC’, uses a type of stem cell called mesenchymal stem cells (MSCs) which have been investigated for various diseases caused by inflammation, such as Crohn’s disease. 

This is the first time the results of using MSCs for Covid-19 patients has been reported. 

The therapy was used in Spain by a number of universities, led by Professor Bernat Soria from the Miguel Hernández University (UMH).


The treatment, called ‘AT-MSC’, uses a type of stem cell called mesenchymal stem cells (MSCs).

Everybody naturally grows these cells. But as Professor Bernat Soria from the Miguel Hernández University (UMH) puts it, ‘the younger, the better’.

The cells are harvested from the fat tissue of liposuction donors, usually women under 50 who have no underlying health conditions.

Scientists mechanically separate the fat tissue on plastic. The mesenchymal stromal cells inside the tissue float up and bind to the plastic.

They are easy to culture, Professor Soria said. ‘In six to eight weeks you have 100million cells and the dose [of AT-MSC] is approximately 1million cells per kilogram.’

MSCs have the ability to differentiate into a variety of cell types, including bone, cartilage and muscle cells, and so are known to have tissue repairing abilities. 

They are typically investigated for the treatment of various inflammatory diseases such as Crohn’s because they help have an anti-inflammatory effect. However, clinical studies investigating the efficacy of MSCs in treating diseases are in preliminary development. 

In the study, 13 critical coronavirus patients were enrolled. They were all white, aged between 47 and 73 years old, and only one patient was a woman.

On a scale of clinical severity designed by the World Health Organization, they scored 6-7. Grade 8 is death. 

The patients were given the treatment AT-MSC having not got any better when given various medicines, including experimental Covid-19 drugs lopinavir/ritonavir, hydroxychloroquine and tocilizumab.

Each received a dose of one million cells per kilo of their body weight and monitored closely. If their condition was not improving, they were given one or more doses.

The results of AT-MSC in coronavirus patients admitted in ICUs were compared with the clinical evolution and mortality of similar cases. 

Therefore it is not the highest standard of drug evaluation – a randomised controlled trial – when two groups either receiving a specific drug or not, are compared.

According to the results, the stem cell therapy improved outcomes without causing any serious side effects.

Nine of the 13 patients showed improvements, and seven were taken off ventilation after an average of 16 days. 

Two of the patients given the stem cell treatment died (15 per cent) compared with 70-85 per cent in a group of ‘similar cases’.  

Professor Soria told MailOnline he did not expect such staggering results – which were published today in The Lancet eClinicalMedicine.

He said: ‘In summary it has been much better that what I expected.’

Professor Soria began his research on the use of cellular therapy during the Asian epidemic of SARS-1 in 2003.

Unlike SARS, the new coronavirus (SARS-CoV-2) doesn’t just cause damage to the lungs. In Covid-19 patients, there are a number of complications that lead to the demise of organs other than the lungs.

SARS-CoV-2 typically causes a depression of the immune system, coupled with a widespread extreme inflammatory response.

The hyper activation of the immune response is called a cytokine storm, and scientists are eager to find treatments to halt its damage to otherwise healthy tissues.

How the 13 patients in the pilot study fared on a timescale - the bottom two died after just four and then 11 days

How the 13 patients in the pilot study fared on a timescale – the bottom two died after just four and then 11 days

MSCs have tissue repair properties because they have the ability to differentiate into a variety of cell types, including bone, cartilage and muscle cells. The researchers also found evidence the MSCs repaired lung tissue in as little as 48 hours. Pictured: Two patients in the pilot study before (A) and 48 hours after receiving treatment (B)

MSCs have tissue repair properties because they have the ability to differentiate into a variety of cell types, including bone, cartilage and muscle cells. The researchers also found evidence the MSCs repaired lung tissue in as little as 48 hours. Pictured: Two patients in the pilot study before (A) and 48 hours after receiving treatment (B)

AT-MSC managed to decrease patients’ inflammation markers, called C-reactive protein and ferritin, five days after the first dose.

Professor Soria expected AT-MSC to help curb the damage caused by the cytokine storm, but also found it ‘restores partially the immune system’. 

It boosted the presence of T cells, which directly attack the virus, and B cells, which trigger antibodies into action. 

This is beneficial because it means the therapy can not only mitigate the complications of the virus, but help to eliminate it from the body at the same time.

MSCs have tissue repair properties because they have the ability to differentiate into a variety of cell types, including bone, cartilage and muscle cells.

The researchers also found evidence the MSCs repaired lung tissue, with chest X-rays, in as little as 48 hours.

This was evident further with a drop in D-dimer, a tissue damage and blood clotting biomarker. 

Professor Soria said: ‘Preliminary data suggest efficacy, but this need a controlled randomized double blind clinical trial to be done.’

The paper said there were 17 clinical trials registered to look at MSCs, which have peaked in interest as a potential Covid-19 treatment. 

Only one other severe Covid-19 patient has ever been reported to have been given MSCs, ‘with favourable outcome’.

Professor Soria and colleagues wrote: ‘Pre-clinical evidence of the potential for MSCs in viral lung infections is still scarce and, in some cases, controversial.

‘It is true that there are no preclinical studies in animal models of SARS-CoV-2 infection and that most preclinical evidence comes from influenza virus infection models.

‘Nevertheless, although results of these studies are not uniformly positive, no adverse events related to cell therapy in this setting has been reported.

‘These results are a proof of concept… These results support conducting a phase 2 randomized controlled trial already under way.’


Meditation helps boosts immunity: Study

  • July 8, 2020

Heartfulness Meditation, a meditation practice adapted from Raja Yoga system, improves immunity against infections and cancer. It is an effective adjunct in the treatment of several autoimmune disorders. In the current context of COVID 19 Pandemic when vaccines have yet not seen light of the day, it has been advocated strongly by medical and other research fraternities that the fundamental defence against the virus is to have strong immunity.

In an article published in the International Journal of Recent Scientific Research, authors Dr. Raja Amarnath G. Director, Critical Care Services – Sree Balaji Medical College, Chennai, Dr. Natwar Sharma, Pediatrics In charge – Saveetha Medical College, Chennai Dr. Prasanthi J., Diabetologist, Chennai, Dr. Sugirtha Jenitha, Critical Care – Sree Balaji Medical College, Dr. Chitra Rajan Consultant Environmental Sustainability – IIT Chennai and Dr. Subbulakshmi Balasubramanian, RRT, Michigan USA have drawn a comparison between stress and immunity.

Commenting on the far reaching benefits of meditation Kamlesh Patel, Guide of Heartfulness said, “meditation should be made an integral part of life, it acts as a silent regulator for all systems in our being – physical, mental, emotional and spiritual to function in harmony. The impact of this is the ability of the body and mind to respond to internal and external stress with extreme effectiveness. Scientific backing forms the core of the offerings at Heartfulness. The recent study that shows Heartfulness meditation helps in improving immunity should be motivating for many to embrace the practice, to help deal with situations like we are facing now as well as to strengthen oneself internally for the future challenges.”

Also read: Let age not decide your immunity level

According to the authors, when stress becomes chronic, many organ systems in the body are affected. Persistent stress results in excessive levels of cortisol and other corticosteroids circulating in the blood for a longer period that produces irregularities in the immune responses. This results in increased susceptibility to infections, increased risk of cancer, tendency to develop an allergy, increased gastrointestinal problems and an increased risk of autoimmune disorders. Chronic stress also leads to anxiety, depression, sleep deprivation, hypertension, cardiovascular diseases, diabetes, and metabolic syndrome.

The authors stress that managing stress through relaxation techniques, meditation, yoga, positive thinking and moulding a healthy lifestyle can dramatically improve mood and strengthen the immune system. They cite several studies, Studies revealed that the relaxation produced after meditation reduces the levels of IL-6, a proinflammatory cytokine produced by T cells, that plays a major role in the pathophysiology of several autoimmune diseases, different types of cancers and Alzheimer’s diseases.

According to them, meditation increases telomerase activity and lengthens telomeres and thus promotes immune cell longevity. Beneficial effects of meditation also include reducing the activity of nuclear factor-kB (NF-kB) which is a mediator in the pathogenesis of certain cancers, arthritis, chronic inflammatory conditions, asthma and neurodegenerative diseases and lowering C – reactive protein levels that are high in lymphoma, systemic lupus erythematosus, arthritis, rheumatoid arthritis and inflammatory bowel disease.

Regular practice of Heartfulness Meditation can aid in stress reduction and general well-being. Shifting the autonomic balance towards parasympathetic from sympathetic and reducing the secretion of stress hormones are the key reasons. Relaxation response produced from meditation reduces metabolic rate, moderates fight or flight response, reduces breathing and heart rate (HR), lowers blood pressure, brings cortisol and lactate levels down, and elevates blood flow to the key internal organs. Heartfulness Meditation alleviates physical and psychological stress and restores mental harmony, and if practised regularly – it is a remarkable medium for maintaining and promoting physical, mental, and spiritual health.

It is the common man’s perspective that most of the traditional methods of meditation are not very easy to follow with all the required diligence. Choosing a simple and effective method suiting the current day’s busy lifestyles appears to be the key to enable better adherence.

Modified Raja Yoga systems like ‘Heartfulness meditation’, which are simple and practised by the majority of spiritual seekers around the world over the last several decades, needs to be explored much deeper through large, controlled trials in this regard.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Do NOT follow this link or you will be banned from the site!